• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Genprex Inc.

    4/1/25 6:50:05 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    NT 10-K 1 gnpx20250401_nt10k.htm FORM NT 10-K gnpx20250401_nt10k.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 12b-25

    SEC FILE NUMBER

       

    001-38244

         
       

    CUSIP NUMBER

     

    NOTIFICATION OF LATE FILING

    372446203

     

    (Check one):

    ☒  Form 10-K

    ☐ Form  20-F

    ☐ Form  11-K

       
     

    ☐  Form 10-Q

    ☐ Form  10-D

    ☐ Form  N-CEN

    ☐  N-CSR

     

     

    For Period Ended: December 31, 2024

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

     

    For the Transition Period Ended:

       

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     


     

    PART I - REGISTRANT INFORMATION

     

    Genprex, Inc.

    Full Name of Registrant

     

    N/A

    Former Name if Applicable

     

    3300 Bee Cave Road, #650-227

    Address of Principal Executive Office (Street and Number)

     

    Austin, TX 78746

    City, State and Zip Code

     

     

     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

     

    (a)

    The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

         

    ☒

    (b)

    The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

         
     

    (c)

    The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Genprex, Inc., a Delaware corporation (the “Company”), was unable to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”) by the prescribed due date without unreasonable effort or expense because of the circumstances described below.

     

    The Company has worked diligently to complete and finalize the 2024 Form 10-K, including the Company’s financial statements to be included therein and related audit procedures necessary for the issuance of such financial statements, so that the 2024 Form 10-K could be filed as soon as possible. However, additional time was required for the Company to complete and finalize the 2024 Form 10-K and the Company’s financial statements.

     

    In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, and as stated in Part I above, the Company represents that the subject 2024 Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date.

     

    PART IV - OTHER INFORMATION

     

    (1)

    Name and telephone number of person to contact in regard to this notification

     
     

    Ryan Confer

     

    (512)

     

    537-7997

     

    (Name)

     

    (Area Code)

     

    (Telephone Number)

     

    (2)

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     
     

    Yes ☒ No ☐

       

     

     

     

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     
     

    Yes ☐ No ☒

     
     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     


     

    Genprex, Inc.

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date:

    April 1, 2025

     

    By:

    /s/ Ryan Confer

           

    Name: Ryan Confer

    Title: President, Chief Executive Officer,

    and Chief Financial Officer

     

     
    Get the next $GNPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moreno Toscano Jose Antonio was granted 9,000 shares, increasing direct ownership by 5,732% to 9,157 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    12/23/25 5:35:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Berger Mark Stanley was granted 28,500 shares, increasing direct ownership by 7,917% to 28,860 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    12/23/25 5:35:14 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, CEO and CFO Confer Ryan M. was granted 45,000 shares, increasing direct ownership by 6,808% to 45,661 units (SEC Form 4)

    4 - Genprex, Inc. (0001595248) (Issuer)

    12/23/25 5:34:21 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    SEC Filings

    View All

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    2/10/26 8:04:05 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    1/9/26 4:58:44 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Genprex Inc.

    S-8 - Genprex, Inc. (0001595248) (Filer)

    1/9/26 4:56:14 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

    Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® Company Adds Additional Acclaim-3 Clinical Trial Site AUSTIN, Texas, Feb. 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that IP Australia, the Australian government agency responsible for administering Australia's intellectual property rights system, has issued a Notice of Acceptance, on February 5, 2026, of the Genprex patent application claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodie

    2/10/26 8:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Provides Clinical Update on Diabetes Gene Therapy Program

    Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas, Jan. 7, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program for GPX-002, the Company's diabetes gene therapy drug candidate, detailing recent achievements and future advancements. This update follows the recent announcement of positive preliminary preclinical data from studies of GPX-002 in both mouse and non-human primate (NHP) models, specifica

    1/7/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

    Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose Levels in Type 2 Diabetic Mice AUSTIN, Texas, Jan. 6, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced preliminary in vivo preclinical proof-of-concept data for GPX-002, the Company's diabetes gene therapy drug candidate which may have the potential for long-term control of Type 1 diabetes (T1D) and Type 2 diabetes (T2D), in a

    1/6/26 7:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    National Securities initiated coverage on Genprex with a new price target

    National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00

    1/26/21 7:48:53 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Genprex Inc.

    SC 13G/A - Genprex, Inc. (0001595248) (Subject)

    10/24/24 12:23:37 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/22/24 12:01:59 PM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Genprex Inc.

    SC 13G - Genprex, Inc. (0001595248) (Subject)

    10/3/24 10:09:50 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

    Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman,

    5/13/24 8:31:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

    Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer AUSTIN, Texas, Aug. 22, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the appointment of Suzanne Thornton-Jones, Ph.D. as Senior Vice President, Regulatory Affairs. Dr. Thornton-Jones will leverage her regulatory expertise to guide and oversee the Company's regulatory submissions and strategy

    8/22/23 7:30:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care